Atorvastatin /Day
Phase 2Small molecule
Atorvastatin /Day is one of 31 small molecule programs targeting Cardiomyopathy. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Cardiomyopathy
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskApproved
Bayer Aspirin
BayerApproved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Zocor
OOrganon and Co
Approved
Cordarone
WWyeth-Lederle Vaccines
Approved
Imuran
LLegacy Health System
Approved
Inpefa
LLexicon Pharmaceuticals
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Atorvastatin /Day. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHotel Dieu de France Hospital